site selection, study design, and operational planning. This article provides an end-to-end process guide for clinical operations, regulatory affairs, and medical affairs professionals working in the US, UK, and EU. It covers how feasibility questionnaires integrate into the clinical trial lifecycle from concept development through close-out, ensuring alignment with regulatory expectations from the FDA, EMA, and MHRA, as well as international standards such as ICH guidelines. Understanding and implementing robust feasibility assessments enhances trial efficiency, regulatory compliance, and scientific validity.

Context and Core Definitions for Feasibility Questionnaire Clinical Trials

The concept of feasibility questionnaire clinical trials refers to the structured assessment of potential clinical trial sites to determine their capability and readiness to conduct a proposed study. This process typically occurs during the early trial lifecycle phase, after concept approval but before site initiation. Key terms include:

• Clinical Trial Site Feasibility: Evaluation of a site’s infrastructure, patient population, staff expertise, and regulatory compliance to support the trial protocol.
• Feasibility Study Clinical Trial: A preliminary investigation, often involving feasibility questionnaires, to assess practical aspects such as recruitment potential and resource availability.
• Codebreak 100 Trial: An example of a complex, multinational trial where rigorous feasibility assessments were essential to site selection and risk mitigation.

Feasibility questionnaires gather quantitative and qualitative data from sites, including patient demographics, prior trial experience, investigational product handling capabilities, and regulatory environment. These data inform decisions on site selection, recruitment strategies, and risk management. Regulatory authorities such as the FDA (US), EMA (EU), and MHRA (UK) expect sponsors to conduct thorough feasibility assessments as part of Good Clinical Practice (GCP) compliance and trial quality assurance.

Regulatory and GCP Expectations in US, EU, and UK

Regulatory frameworks in the US, EU, and UK emphasize the importance of feasibility assessments in ensuring trial integrity and participant safety. The FDA references feasibility considerations in 21 CFR Part 312 and 21 CFR Part 812, focusing on site qualifications and investigational product handling. The ICH E6(R3) guideline on Good Clinical Practice mandates that sponsors ensure sites have adequate resources and capabilities before trial initiation.

The EU Clinical Trials Regulation (EU-CTR 536/2014) requires sponsors to submit detailed site feasibility data as part of the trial application dossier, emphasizing harmonized standards across member states. The MHRA in the UK aligns closely with EMA and ICH standards, requiring documented feasibility assessments to support site selection and risk-based monitoring plans.

Sponsors, Contract Research Organizations (CROs), and sites must operationalize these requirements by implementing standardized feasibility questionnaires, maintaining documentation for inspections, and integrating feasibility data into trial master files. This ensures compliance with regulatory expectations and facilitates efficient trial conduct.

Practical Design and Operational Considerations for Feasibility Questionnaires

Designing an effective feasibility questionnaire requires a multidisciplinary approach involving clinical operations, regulatory affairs, and medical affairs teams. Key steps include:

1. Define Objectives: Clarify what information is needed to assess site suitability, such as patient availability, previous trial experience, and logistical capabilities.
2. Develop Questionnaire Content: Include sections on site infrastructure, staff qualifications, regulatory environment, recruitment projections, and investigational product management.
3. Customize for Regions: Adapt questionnaires to reflect US, EU, and UK regulatory nuances, such as local ethics committee processes or data privacy requirements.
4. Distribute and Collect Data: Use electronic platforms where possible to streamline data collection and ensure data integrity.
5. Analyze Responses: Evaluate site feasibility quantitatively and qualitatively, considering recruitment timelines, risk factors, and compliance readiness.
6. Document Decisions: Maintain clear records of site selection rationale, including feasibility questionnaire results, to support regulatory submissions and audits.

Roles and responsibilities are typically divided as follows: sponsors oversee questionnaire development and final site selection; CROs may manage distribution and data collection; principal investigators and site staff provide accurate responses and supporting documentation. For example, in the codebreak 100 trial, a detailed feasibility questionnaire was pivotal in identifying sites with the capacity to manage complex blinding and randomization procedures.

Common Pitfalls, Inspection Findings, and How to Avoid Them

Regulatory inspections frequently identify deficiencies related to feasibility questionnaires and site selection processes. Common pitfalls include:

• Incomplete or Inaccurate Data: Sites providing insufficient or misleading information, leading to unrealistic recruitment projections or resource assumptions.
• Lack of Documentation: Failure to retain completed questionnaires or rationale for site selection, compromising audit trails.
• Inadequate Regional Adaptation: Using generic questionnaires that do not address local regulatory or operational requirements.
• Insufficient Training: Site staff unfamiliar with questionnaire content or the importance of precise responses.

These issues can result in delayed recruitment, protocol deviations, or regulatory non-compliance. Prevention strategies include:

• Implementing Standard Operating Procedures (SOPs) for feasibility assessments.
• Providing targeted training for site staff and study teams on questionnaire completion and review.
• Conducting quality checks and follow-up queries to clarify ambiguous responses.
• Maintaining comprehensive documentation accessible for regulatory inspections.

Proactive management of these risks enhances data integrity and supports successful trial outcomes.

US vs EU vs UK Nuances and Real-World Case Examples

While the core principles of feasibility questionnaire clinical trials are consistent across regions, several important nuances exist:

• US (FDA): Emphasizes site qualifications under 21 CFR and expects clear documentation of investigational product handling and informed consent processes. Feasibility questionnaires often include detailed questions on Institutional Review Board (IRB) timelines and FDA-specific regulatory experience.
• EU (EMA/EU-CTR): Requires harmonized feasibility data submission as part of the centralized trial application. Regional variations in ethics committee structures and data protection laws (GDPR) require tailored questionnaire sections.
• UK (MHRA): Post-Brexit, MHRA maintains alignment with ICH and EMA standards but has specific requirements for site feasibility related to UK ethics and Health Research Authority (HRA) approvals.

Case Example 1: In a multinational oncology trial resembling the codebreak 100 trial, failure to adapt feasibility questionnaires to GDPR requirements in EU sites led to delays in site activation. Early engagement with regulatory affairs and local site teams mitigated these issues by revising questionnaires and consent processes.

Case Example 2: A US-based cardiovascular trial experienced recruitment shortfalls due to overestimation of patient availability in feasibility questionnaires. Implementation of a more rigorous feasibility review process, including site visits and patient database verification, improved accuracy in subsequent studies.

Multinational teams can harmonize their approach by developing a core questionnaire template supplemented with region-specific modules, ensuring compliance and operational efficiency.

Implementation Roadmap and Best-Practice Checklist

To effectively implement feasibility questionnaire clinical trials within the trial lifecycle, follow this stepwise roadmap:

1. Initiate Feasibility Planning: Define objectives and scope aligned with protocol requirements and regulatory expectations.
2. Develop Questionnaire Template: Collaborate with cross-functional teams to include clinical, operational, and regulatory items.
3. Incorporate Regional Adaptations: Customize for US, EU, and UK requirements, including data privacy and ethics considerations.
4. Train Study and Site Teams: Conduct targeted training on questionnaire completion and importance.
5. Distribute and Collect Responses: Use electronic data capture tools to enhance data quality and traceability.
6. Review and Validate Data: Perform quality control checks and follow-up queries as needed.
7. Document Site Selection Decisions: Archive feasibility data and rationale in trial master files.
8. Integrate Feasibility Data into Monitoring Plans: Use findings to inform risk-based monitoring and site support strategies.

Best-Practice Checklist:

• Use a standardized, comprehensive feasibility questionnaire template with regional modules.
• Ensure all feasibility data are documented and stored per regulatory requirements.
• Provide training to sites and study teams on the importance and completion of feasibility questionnaires.
• Implement quality control processes for data review and validation.
• Align feasibility assessments with protocol design and recruitment strategies.
• Maintain clear audit trails to support regulatory inspections.

Comparison of Feasibility Questionnaire Clinical Trials Across US, EU, and UK

Aspect	US (FDA)	EU (EMA/EU-CTR)	UK (MHRA)
Regulatory Framework	21 CFR Parts 312 & 812; ICH E6	EU-CTR 536/2014; ICH E6	MHRA GCP Guidance; ICH E6
Feasibility Data Focus	Site qualifications, IRB timelines, investigational product handling	Harmonized site data, ethics committee processes, GDPR compliance	UK ethics and HRA approvals, data privacy aligned with UK GDPR
Documentation Expectations	Detailed site feasibility records in TMF; FDA inspection readiness	Submission of feasibility data with trial application; audit trails	Comprehensive feasibility documentation; MHRA inspection compliance
Operational Considerations	Electronic questionnaires; site qualification visits encouraged	Standardized templates with regional adaptations; electronic data capture	Alignment with UK-specific regulatory timelines; training emphasis

Key Takeaways for Clinical Trial Teams

• Implement standardized feasibility questionnaires tailored to US, EU, and UK regulatory requirements to optimize site selection and trial efficiency.
• Maintain thorough documentation of feasibility assessments to meet FDA, EMA, and MHRA inspection expectations and reduce regulatory risk.
• Integrate feasibility questionnaire training into site initiation and study team education to enhance data quality and compliance.
• Harmonize multinational feasibility processes by developing core templates with region-specific adaptations, supporting consistent global trial execution.